Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

$24.99

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Solvency Ratios (Summary)

Abbott Laboratories, solvency ratios (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Debt Ratios
Debt to equity
Debt to capital
Debt to assets
Financial leverage
Coverage Ratios
Interest coverage

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


Analysis of the solvency ratios reveals a consistent period of deleveraging from early 2022 through the end of 2025, followed by a significant and abrupt increase in leverage in the first quarter of 2026.

Debt-to-Equity and Capitalization Trends
A steady decline is observed in the debt-to-equity ratio, which fell from 0.48 in March 2022 to a low of 0.25 by December 2025. Similarly, the debt-to-capital ratio decreased from 0.33 to 0.20 over the same period. This pattern indicates a sustained reduction in reliance on borrowed funds relative to shareholders' equity and total capital.
Asset Management and Leverage
The debt-to-assets ratio exhibited a mirrored downward trend, decreasing from 0.23 in March 2022 to 0.15 in December 2025. Concurrently, financial leverage declined from 2.09 to 1.66, suggesting an improvement in the overall solvency profile and a reduced risk associated with the asset-to-equity structure throughout the majority of the analyzed period.
Interest Coverage and Debt Servicing
Interest coverage showed higher volatility compared to the leverage ratios. After starting at 18.10 in March 2022, the ratio reached a trough of 10.79 in September 2023 before recovering strongly to 18.17 by December 2025. This indicates that while the margin for debt servicing narrowed mid-period, the ability to cover interest expenses returned to peak levels by the end of 2025.
Analysis of the March 2026 Pivot
A sharp reversal in all solvency metrics occurred in March 2026. The debt-to-equity ratio spiked to 0.65, debt-to-capital rose to 0.40, and debt-to-assets increased to 0.31. Financial leverage returned to 2.12, surpassing the peak observed in 2022. This sudden shift suggests a major financing event, such as a substantial debt issuance or a large-scale acquisition, resulting in a rapid increase in long-term obligations.

Debt Ratios


Coverage Ratios


Debt to Equity

Abbott Laboratories, debt to equity calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Short-term borrowings
Current portion of long-term debt
Long-term debt, excluding current portion
Total debt
 
Total Abbott shareholders’ investment
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Debt to equity = Total debt ÷ Total Abbott shareholders’ investment
= ÷ =

2 Click competitor name to see calculations.


The solvency profile reflects a prolonged period of strategic deleveraging and equity growth followed by a sudden and significant increase in liabilities in the final reported quarter. From March 2022 through December 2025, the capital structure transitioned toward a more conservative position, characterized by falling debt levels and rising shareholder investment.

Total Debt Trajectory
Total debt showed a consistent downward trend for the majority of the analyzed period, declining from $17,090 million in March 2022 to $12,929 million by December 2025. This steady reduction in obligations was abruptly reversed in March 2026, where total debt surged to $34,047 million, marking a sharp increase in the company's total liabilities.
Shareholders' Investment Growth
Total shareholders' investment exhibited sustained growth, rising from $35,399 million in March 2022 to $52,130 million by December 2025. A notable acceleration in equity accumulation occurred between September 2024 and December 2024, where investment increased by approximately $7.87 billion in a single quarter, contributing to a stronger equity base.
Debt to Equity Ratio Analysis
The debt to equity ratio improved steadily from 0.48 in March 2022 to a minimum of 0.25 by December 2025, indicating a reduced reliance on debt financing. This period of increasing solvency was terminated in March 2026, as the ratio spiked to 0.65. This shift indicates a rapid increase in financial leverage, moving the solvency position from a highly conservative state to a significantly more leveraged one.

Debt to Capital

Abbott Laboratories, debt to capital calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Short-term borrowings
Current portion of long-term debt
Long-term debt, excluding current portion
Total debt
Total Abbott shareholders’ investment
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


From March 2022 through December 2025, a consistent trend of deleveraging is observed. The Debt to Capital ratio experienced a steady decline, moving from a peak of 0.33 in early 2022 to a low of 0.20 by the end of 2025, indicating a strategic reduction in reliance on borrowed funds relative to total capital.

Total Debt Dynamics
Total debt decreased progressively from 17,090 million US dollars in March 2022 to 12,929 million US dollars by December 2025. This reduction reflects a sustained decrease in total liabilities over the four-year span.
Total Capital Growth
Total capital remained relatively stable between 52,000 and 54,000 million US dollars from 2022 to early 2024, followed by an expansion to 65,059 million US dollars by December 2025. The concurrent decrease in debt and increase in total capital contributed to the systematic compression of the solvency ratio.
Solvency Ratio Performance
The Debt to Capital ratio reached its minimum threshold of 0.20 in the latter half of 2025, signaling an improved solvency position and increased financial stability during this period.

A significant shift in the capital structure occurred on March 31, 2026. Total debt surged to 34,047 million US dollars, and total capital rose to 86,108 million US dollars. This resulted in a sharp increase of the Debt to Capital ratio to 0.40, marking the highest level of leverage recorded in the analyzed timeframe. Such a substantial and abrupt increase suggests a major corporate event, potentially a large-scale acquisition or a significant strategic financing initiative.


Debt to Assets

Abbott Laboratories, debt to assets calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Short-term borrowings
Current portion of long-term debt
Long-term debt, excluding current portion
Total debt
 
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


The financial data indicates a prolonged period of deleveraging and asset growth from early 2022 through late 2025, followed by a significant shift in the capital structure in the first quarter of 2026. For the majority of the analyzed timeframe, the solvency position improved as total debt decreased while total assets generally trended upward.

Debt Reduction Trend
Total debt exhibited a steady downward trajectory for most of the period, declining from 17,090 million US$ in March 2022 to a low of 12,929 million US$ by December 2025. This consistent reduction in liabilities suggests a focused effort to lower the company's overall leverage.
Asset Growth Patterns
Total assets remained relatively stable between 72,000 and 74,000 million US$ from March 2022 through September 2024. However, a period of accelerated growth began in December 2024, with assets rising to 86,713 million US$ by December 2025, indicating an expansion of the company's resource base.
Debt to Assets Ratio Analysis
The debt to assets ratio remained constant at 0.23 for the first several quarters before beginning a gradual decline. The ratio reached its lowest point of 0.15 in the second half of 2025, reflecting a stronger solvency position resulting from the simultaneous decrease in debt and increase in assets.
Q1 2026 Capital Shift
A substantial deviation is observed on March 31, 2026, characterized by a sharp increase in both total debt, which rose to 34,047 million US$, and total assets, which climbed to 110,429 million US$. Consequently, the debt to assets ratio increased abruptly to 0.31, marking the highest leverage level recorded in the provided period.

Financial Leverage

Abbott Laboratories, financial leverage calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Total assets
Total Abbott shareholders’ investment
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Financial leverage = Total assets ÷ Total Abbott shareholders’ investment
= ÷ =

2 Click competitor name to see calculations.


The solvency profile reflects a period of consistent deleveraging followed by a significant shift in capital structure in early 2026. For the majority of the analyzed period, there was a sustained reduction in financial risk as the reliance on debt relative to equity diminished.

Financial Leverage Trajectory
A consistent downward trend in financial leverage is observed from March 31, 2022, when the ratio stood at 2.09, reaching a minimum of 1.65 by September 30, 2025. This decline indicates a strengthening of the solvency position and a strategic shift toward a more equity-heavy capital structure over a three-year period.
Asset and Equity Growth
Total assets remained relatively stable between 72 billion and 74 billion US dollars from early 2022 through September 2024. However, a notable expansion began in December 2024, with assets increasing to 81.4 billion US dollars and continuing a steep climb to 110.4 billion US dollars by March 31, 2026. Parallel to this, shareholders' investment grew steadily from 35.4 billion US dollars in March 2022 to 52.1 billion US dollars in March 2026, with a significant jump occurring between September and December 2024.
Capital Structure Shift (Q1 2026)
A sharp reversal in the deleveraging trend occurred on March 31, 2026, where financial leverage spiked to 2.12. This increase coincides with a substantial surge in total assets, which grew by approximately 28.7 billion US dollars in a single quarter. This pattern suggests a major capital event, such as a large-scale acquisition or significant new debt issuance, which temporarily elevated the financial leverage ratio above the levels seen since early 2022.

Interest Coverage

Abbott Laboratories, interest coverage calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Net earnings
Add: Income tax expense
Add: Interest expense
Earnings before interest and tax (EBIT)
Solvency Ratio
Interest coverage1
Benchmarks
Interest Coverage, Competitors2
Elevance Health Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Interest coverage = (EBITQ1 2026 + EBITQ4 2025 + EBITQ3 2025 + EBITQ2 2025) ÷ (Interest expenseQ1 2026 + Interest expenseQ4 2025 + Interest expenseQ3 2025 + Interest expenseQ2 2025)
= ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The interest coverage ratio exhibits a U-shaped trajectory over the analyzed period, characterized by a significant decline from early 2022 through late 2023, followed by a steady recovery until the end of 2025, before experiencing a sharp contraction in the first quarter of 2026.

Earnings Before Interest and Tax (EBIT) Trends
EBIT experienced a sharp decline from 3,007 million USD in March 2022 to a low of 1,474 million USD by December 2022. A gradual recovery ensued, with earnings climbing steadily throughout 2023 and 2024, eventually peaking at 2,478 million USD in December 2025. This upward trend was interrupted in March 2026, when EBIT fell to 1,623 million USD.
Interest Expense Dynamics
Interest expenses showed an initial upward trend, reaching a peak of 166 million USD in September 2023. Subsequently, a period of cost reduction was observed throughout 2024 and 2025, with expenses decreasing to 120 million USD by December 2025. A notable spike occurred in March 2026, with expenses rising to 174 million USD, the highest level recorded in the period analyzed.
Interest Coverage Ratio Analysis
The interest coverage ratio declined from a high of 20.07 in June 2022 to a minimum of 10.79 by September 2023, reflecting the combined impact of diminishing operating income and rising interest costs. A consistent recovery period followed, with the ratio climbing back to 18.17 by December 2025, driven by the dual effect of expanding EBIT and reduced debt servicing costs. The period concluded with a decline to 16.18 in March 2026, precipitated by the simultaneous drop in earnings and the increase in interest expenses.